Shedding or a Flare? CCCA After a Hair Transplant

You have CCCA. You had a hair transplant. Now hair is coming out, and you need to know which of two completely different things is happening: the ordinary shedding that follows surgery, or your CCCA becoming active again. One you wait out. The other needs treating, and waiting costs you follicles.

We looked for a page that answers this. We could not find one, anywhere, in any language we can read. This is our attempt, and the first thing it will do is show you how little anybody knows.

Why getting this wrong is expensive

Shock loss is your existing hair being pushed into its resting phase by the stress of surgery. The follicle is still there. We have written about it at length on our shock loss page, and the short version is that in the published cases it came back.

CCCA is different in kind. It is a scarring alopecia: when it is active it destroys the follicle and replaces it with scar tissue. Hair lost that way does not return, and no surgery puts it back. Treating an active flare early is the whole game.

So the two look similar in the mirror and are opposite in what they demand of you. Waiting calmly is correct for one and costly for the other.

First, how much is actually known about operating on a CCCA scalp

Less than almost anyone is told. We want to put this before anything else, because it frames every other sentence on this page.

A systematic review searching the literature from 1960 onwards found that hair transplantation had been successful in three patients previously diagnosed with CCCA. Those cases used a combination of pre-transplant tests, a biopsy of the recipient site, and between six months and two years of anti-inflammatory treatment after the transplant.^[1,2]

Three people. Not three studies — three patients, across everything indexed since 1960. Clinics around the world offer this operation to women with CCCA, and the published experience behind it would fit around a small table.

That is not an argument against having it done. Those patients grew hair and kept it, and a scarred scalp has no other surgical option. It is an argument against anybody — us included — discussing it in the voice of someone quoting a trial.

Widen the lens to scarring alopecias of every kind and the numbers are still small, but they are no longer all good news. The same review included 15 reports covering 34 patients with primary scarring alopecia of all types. Twenty-six experienced moderate to positive results, while 8 experienced negative results or recurrence of disease.^[1]

Read that carefully. Those eight are not all CCCA patients, and the review lumps “negative results” together with “recurrence of disease”, so we cannot tell you how many were the disease coming back. What it does establish is that the disease coming back after surgery is a thing that happens and gets published.

And the literature is flattering itself

The review names positive reporting bias as the biggest challenge it encountered: only cases with viable and positive outcomes are reported in this literature. Its authors conclude that no concrete, evidence-based recommendations can be made on hair transplantation in primary scarring alopecia at this time.^[1]

A clinic has an obvious reason not to mention that the evidence for the operation it sells comes from a literature that mostly publishes its successes. It is the single most useful sentence in that review for somebody deciding, so here it is.

There is now a way to score whether your CCCA is active

This is the most useful thing on this page, and it is recent enough that your own doctor may not have met it.

A scoring tool for CCCA disease activity was published in 2025. The C-CAT scores five things from 0 to 2 each: pain, itching, redness, scalp resistance and disease progression. In the 82 patients it was developed on, all of them African-American and 98 percent women, the average score at the first visit was 3.3; after treatment 88 percent improved and 48 percent reached a score of zero, which the tool defines as remission, over an average of 195 days.^[3]

Two things about that are worth pausing on.

The first is that it gives you a question you can actually ask: “What is my C-CAT score, and what was it last time?” A number that moves is a different conversation from “does it feel better?”.

The second is who it was built on. Every other study behind our shock loss page was done on Japanese, Korean or Indian patients, or did not record hair type at all. This one is 82 patients, almost all women, all of them African-American. It is the only source in our library measured on the people we actually treat.

And here is exactly where it stops

The C-CAT was built to guide and track medical treatment. Hair transplantation, surgery and post-operative shedding are not mentioned anywhere in the paper that introduces it, and it offers no way to tell a flare apart from shedding caused by something else.^[3]

From the other direction, the surgical literature has the matching hole. The authors of the systematic review state that they were unable to find evidence on how to precisely diagnose disease activity, or on when after disease activity it is appropriate to perform surgery. They also state that the commonly suggested two-year rule for hair transplant surgery after disease activity was not substantiated in their review.^[1]

So: a tool that scores the disease but ignores surgery, and a review of surgery that cannot find a way to score the disease. The two questions have never been put together, which is why the thing you searched for does not exist.

We searched PubMed on 17 September 2026 for anything that would tell post-operative shedding apart from CCCA becoming active again. We found nothing. A tool for scoring CCCA activity does exist, published in 2025, but it does not mention surgery; and the systematic review of hair transplantation in scarring alopecia states that its authors could not find evidence on how to diagnose disease activity. The two questions have not been addressed together.

What the neighbouring disease can tell us, and one uncomfortable finding

In a series of 32 patients with lichen planopilaris, a different scarring alopecia, surgery was performed only on inactive disease, and graft survival was 78.62 percent at twelve months and 79.96 percent at twenty-four months. The histopathology variables examined at the time of transplantation, including epidermal atrophy, fibrosis and inflammatory infiltrate, were not found to have any effect on graft survival.^[4]

That is lichen planopilaris, not CCCA, and it cannot be carried across — different disease, different course, different patients. We include it for the last part of the sentence, which cuts against us.

The obvious answer to “how do you know my disease is quiet enough to operate on?” is “we take a biopsy”. In the one series that checked whether the biopsy findings predicted how the grafts did, they did not. That does not make biopsy useless — it is how CCCA is confirmed in the first place, and how it is told apart from other things. It does mean a surgeon who offers a biopsy as a guarantee is offering you something the evidence has not supported.

What we will not tell you

• Which of the two is happening to you. Nobody can do that from a website, and anyone who offers to is guessing.
• A success rate for hair transplantation in CCCA. Three published patients do not make a rate, and no arithmetic on three people is honest.
• That your CCCA will not come back after surgery. Recurrence after surgery is documented in the scarring alopecias, and nobody knows how often.
• That a biopsy before surgery guarantees a good outcome. In the only series that tested that assumption, it did not hold.
• A safe waiting period. The commonly quoted two-year rule was examined in a systematic review and not substantiated.

What to ask — here or anywhere

1. What is my C-CAT score today? If the answer is a shrug rather than a number or a reason, you have learned something.
2. How will we tell a flare from post-operative shedding if it happens? There is no published answer, so listen for a plan rather than a reassurance. A good plan names what will be examined and when.
3. How long has my disease been quiet, and how was that judged? Symptoms, photographs, biopsy, trichoscopy — ask which, and over what period.
4. What treatment continues after the operation, and for how long? In the three published CCCA cases, anti-inflammatory treatment carried on for between six months and two years afterwards.
5. How many CCCA patients have you operated on, and what happened to them? Compare the answer with three, which is the whole published world.
6. Am I a candidate at all? Our before you book page asks the six questions that decide it, including whether you form raised scars easily.

If you want these questions answered about your own scalp, send them to us and we will answer in writing, including where we do not know. Our record of what we can and cannot evidence is on the verification page, and the background reading is on our CCCA page.